-
公开(公告)号：US20060153916A1
公开(公告)日：2006-07-13
申请号：US10522989
申请日：2003-08-01
申请人： Navin Vaya , Rajesh Karan , Sunil Nadkarni , Vinod Qupta
发明人： Navin Vaya , Rajesh Karan , Sunil Nadkarni , Vinod Qupta
IPC分类号： A61K9/26
CPC分类号： A61K9/209 , A61K9/2077 , A61K9/2081 , A61K31/155 , A61K31/19 , A61K31/22 , A61K31/4025 , A61K31/455 , A61K31/53
摘要： A dosage form comprising of a high dose, high solubility active ingredient as modified release and a low dose active ingredient as immediate release where the weight ratio of immediate release active ingredient and modified release active ingredient is from 1:10 to 1:15000 and the weight of modified release active ingredient per unit is from 500 mg to 1500 mg; a process for preparing the dosage form.
摘要翻译： 一种剂型，其包含高剂量，高溶解度的活性成分作为调节释放剂和低剂量活性成分作为立即释放，其中速释活性成分和释放活性成分的重量比为1:10至1:15000， 每单位改性释放活性成分的重量为500mg至1500mg; 制备剂型的方法。
-
公开(公告)号：US20060018934A1
公开(公告)日：2006-01-26
申请号：US11134632
申请日：2005-05-19
申请人： Navin Vaya , Rajesh Karan , Sunil Nadkarni , Vinod Gupta
发明人： Navin Vaya , Rajesh Karan , Sunil Nadkarni , Vinod Gupta
CPC分类号： A61K9/2081 , A61K9/5021
摘要： A novel modified release dosage form comprising of a high solubility active ingredient, which utilizes dual retard technique to effectively reduce the quantity of release controlling agents. Present invention can optionally comprise additionally another active ingredient as an immediate release form or modified release form. Present invention also relates to a process for preparing the said formulation.
摘要翻译： 一种新的改性释放剂型，其包含高溶解度活性成分，其利用双延迟技术来有效减少释放控制剂的量。 本发明可任选地另外包含作为立即释放形式或改变释放形式的另一活性成分。 本发明还涉及制备所述制剂的方法。
-
公开(公告)号：US20060018933A1
公开(公告)日：2006-01-26
申请号：US11134631
申请日：2005-05-19
申请人： Navin Vaya , Rajesh Karan , Sunil Nadkarni , Vinod Gupta
发明人： Navin Vaya , Rajesh Karan , Sunil Nadkarni , Vinod Gupta
CPC分类号： A61K31/455 , A61K9/2081 , A61K31/155 , A61K31/19
摘要： A novel modified release dosage form comprising of a high solubility active ingredient, which utilizes dual retard technique to effectively reduce the quantity of release controlling agents. Present invention can optionally comprise additionally another active ingredient as an immediate release form or modified release form. Present invention also relates to a process for preparing the said formulation.
-
公开(公告)号：US20060024365A1
公开(公告)日：2006-02-02
申请号：US11134633
申请日：2005-05-19
申请人： Navin Vaya , Rajesh Karan , Sunil Sadanand , Vinod Gupta
发明人： Navin Vaya , Rajesh Karan , Sunil Sadanand , Vinod Gupta
IPC分类号： A61K9/22
CPC分类号： A61K9/209 , A61K9/2077 , A61K9/2081 , A61K31/155 , A61K31/19 , A61K31/22 , A61K31/4025 , A61K31/455 , A61K31/53
摘要： A dosage form comprising of a high dose, high solubility active ingredient as modified release and a low dose active ingredient as immediate release where the weight ratio of immediate release active ingredient and modified release active ingredient is from 1:10 to 1:15000 and the weight of modified release active ingredient per unit is from 500 mg to 1500 mg; a process for preparing the dosage form.
-
公开(公告)号：US20140142153A1
公开(公告)日：2014-05-22
申请号：US13981262
申请日：2012-01-25
申请人： Chandrasekhar Kocherlakota , Tarun Singh , Nagaraju Banda , Nirmal Khati , Sachin Sharma , Prasad Vure , Aparna Mulupuru , Navin Vaya , Amit Anil Charkha
发明人： Chandrasekhar Kocherlakota , Tarun Singh , Nagaraju Banda , Nirmal Khati , Sachin Sharma , Prasad Vure , Aparna Mulupuru , Navin Vaya , Amit Anil Charkha
IPC分类号： A61K31/4184
CPC分类号： A61K31/4184 , A61K9/19 , A61K47/26
摘要： Aspects of the present appliction relate to pharmaceutical formulations comprising bendamustine or its pharmaceutically acceptable salts, isomers, racemates, enantiomers, hydrates, solvates, metabolites, polymorphs, and mixtures therof, suitable for phamaceutical use. Aspects further provide methods of producing stable bendamustine compositions.
摘要翻译： 本发明的方面涉及包含苯达莫司汀或其药学上可接受的盐，异构体，外消旋体，对映异构体，水合物，溶剂化物，代谢物，多晶型物和适于制药用途的混合物的药物制剂。 方面还提供了生产稳定的苯达莫司汀组合物的方法。
-
公开(公告)号：US07939102B2
公开(公告)日：2011-05-10
申请号：US10452772
申请日：2003-06-02
IPC分类号： A61K9/26
CPC分类号： A61K9/2081 , A61K9/0056 , A61K9/5078 , A61K31/53
摘要： Rapidly disintegrating multiparticulate controlled release formulations of lamotrigine having an improved pharmacokinetic profile and improved patient compliance, and process of preparing the formulations. It provides better control of blood plasma levels than conventional tablet formulations that is administered once or more times a day.
摘要翻译： 具有改善的药代动力学特征和改善的患者依从性的拉莫三嗪的快速分解的多颗粒控制释放制剂以及制备制剂的方法。 它比一天一次或多次施用的常规片剂制剂更好地控制血浆水平。
-
公开(公告)号：US08216609B2
公开(公告)日：2012-07-10
申请号：US10630348
申请日：2003-07-29
CPC分类号： A61K31/455 , A61K9/2081 , A61K31/155 , A61K31/19
摘要： A novel modified release dosage form comprising of a high solubility active ingredient, which utilizes dual retard technique to effectively reduce the quantity of release controlling agents; a process for preparing the dosage form.
摘要翻译： 一种新型改性释放剂型，其包含高溶解性活性成分，其利用双延迟技术有效地减少释放控制剂的量; 制备剂型的方法。
-
公开(公告)号：US07985422B2
公开(公告)日：2011-07-26
申请号：US10630446
申请日：2003-07-29
CPC分类号： A61K9/209 , A61K9/2077 , A61K9/2081 , A61K31/155 , A61K31/19 , A61K31/22 , A61K31/4025 , A61K31/455 , A61K31/53
摘要： A dosage form comprising of a high dose, high solubility active ingredient as modified release and a low dose active ingredient as immediate release where the weight ratio of immediate release active ingredient and modified release active ingredient is from 1:10 to 1:15000 and the weight of modified release active ingredient per unit is from 500 mg to 1500 mg; a process for preparing the dosage form.
摘要翻译： 一种剂型，其包含高剂量，高溶解度的活性成分作为调节释放剂和低剂量活性成分作为立即释放，其中速释活性成分和释放活性成分的重量比为1:10至1:15000， 每单位改性释放活性成分的重量为500mg至1500mg; 制备剂型的方法。
-
公开(公告)号：US08268352B2
公开(公告)日：2012-09-18
申请号：US11134632
申请日：2005-05-19
CPC分类号： A61K9/2081 , A61K9/5021
摘要： A novel modified release dosage form comprising of a high solubility active ingredient, which utilizes dual retard technique to effectively reduce the quantity of release controlling agents. Present invention can optionally comprise additionally another active ingredient as an immediate release form or modified release form. Present invention also relates to a process for preparing the said formulation.
摘要翻译： 一种新的改性释放剂型，其包含高溶解度活性成分，其利用双延迟技术来有效减少释放控制剂的量。 本发明可任选地另外包含作为立即释放形式或改变释放形式的另一活性成分。 本发明还涉及制备所述制剂的方法。
-
10.发明授权Dosage form for high dose-high solubility active ingredients that provides for immediate release and modified release of the active ingredients 有权用于高剂量 - 高溶解度活性成分的剂型，可提供活性成分的即时释放和释放公开(公告)号：US08263125B2
公开(公告)日：2012-09-11
申请号：US11134633
申请日：2005-05-19
CPC分类号： A61K9/209 , A61K9/2077 , A61K9/2081 , A61K31/155 , A61K31/19 , A61K31/22 , A61K31/4025 , A61K31/455 , A61K31/53
摘要： A dosage form comprising of a high dose, high solubility active ingredient as modified release and a low dose active ingredient as immediate release where the weight ratio of immediate release active ingredient and modified release active ingredient is from 1:10 to 1:15000 and the weight of modified release active ingredient per unit is from 500 mg to 1500 mg; a process for preparing the dosage form.
摘要翻译： 一种剂型，其包含高剂量，高溶解度的活性成分作为调节释放剂和低剂量活性成分作为立即释放，其中速释活性成分和释放活性成分的重量比为1:10至1:15000， 每单位改性释放活性成分的重量为500mg至1500mg; 制备剂型的方法。
-
-
-
-
-
-
-
-
-
搜索结果
13 条记录 (耗时 0.042 秒)